Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
While speculative tech stories often capture headlines, Ashtead Technology Holdings (LON:AT.) presents a compelling case built on profitability and sustained growth. With EPS soaring 57% annually over three years and significant insider investment, the subsea equipment specialist is drawing attention from discerning investors.
The U.S. Air Force Research Laboratory has awarded Palladyne AI a contract for its HANGTIME project, marking a significant expansion of the company's autonomous swarm software from ground and air assets into the space domain. The deal validates the company's core technology but comes as investors weigh its growth potential against ongoing financial challenges.
Chinese authorities have approved ByteDance, Alibaba, and Tencent to purchase over 400,000 of NVIDIA's flagship H200 AI chips, signaling a pragmatic shift in Beijing's approach to balancing advanced U.S. technology with domestic chip ambitions.
Analysts highlight Credo Technology Group (CRDO) as a core beneficiary of soaring cloud and AI data center spending, with revenue projected to nearly triple in FY2026 amid industry-wide capex surge.
As major tech firms announce significant layoffs across Washington, the region grapples with a fundamental question: Is this a temporary downturn or a structural pivot toward AI and new industries? The impact ripples far beyond corporate campuses, threatening the vitality of local small businesses that built their models on tech's explosive growth.
Amid global market uncertainty, savvy investors are shifting focus to Asia's resilient technology sector, where companies like Optowide Technologies, Zhejiang Century Huatong, and Digital Garage are demonstrating robust innovation and growth potential despite broader economic headwinds.
Opendoor Technologies appoints a new CEO to spearhead a strategic pivot, placing artificial intelligence at the core of its home buying and selling operations to refine pricing, manage risk, and challenge traditional real estate players.
Asian equities staged a strong recovery on Tuesday, with South Korea's Kospi and Japan's Nikkei leading gains as investors returned to tech stocks. The rebound follows recent volatility, with markets now focused on corporate earnings and geopolitical risks.
As Fortive prepares to release its fourth-quarter results, investors are weighing slowing revenue growth projections against a backdrop of robust peer performance and cautious analyst sentiment. The industrial technology firm's ability to meet or exceed forecasts could signal its resilience in a fluctuating market.
As Vishay Intertechnology prepares to release its fourth-quarter results, investors are weighing the chipmaker's recent performance against a backdrop of industry-wide gains and mixed signals from peers.
Bio-Techne prepares to report quarterly earnings against a backdrop of declining revenue projections and mixed performances from life sciences peers.
Across India's villages and small towns, a new generation of workers is logging on after sunset to label the data that trains the world's most advanced AI systems. This quiet workforce, many of them women and first-generation graduates, is finding economic opportunity while reshaping global tech's supply chain.
Universal Technical Institute (NYSE: UTI) is scheduled to release its fourth-quarter earnings after Wednesday's market close. Investors are watching for signs of sustained growth in the vocational education sector as economic conditions shift.
As TTM Technologies prepares to release its quarterly results, analysts anticipate sustained revenue growth and robust performance in the competitive PCB manufacturing sector.
Amid a volatile tech landscape, Opera Limited (OPRA) presents a compelling, if risky, value proposition. With a profitable core business, a clean balance sheet, and a potentially undervalued stake in African fintech giant Opay, some investors see significant upside despite concerns over revenue concentration and market disruption.
While flashy jets and missiles capture public attention, L3Harris Technologies operates in the critical, unseen layers of connectivity and electronic warfare. As global tensions and technological threats evolve, its role as a foundational enabler of next-generation defense systems is driving a compelling investment thesis centered on resilience and information dominance.
Bio-Techne (TECH) gains market attention with the launch of its Cultrex Synthetic Hydrogel, a key innovation for 3D cell research. While the product debut coincides with recent share price strength, longer-term returns tell a more complex story for investors.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
